27
271980.KO Jeil Pharmaceutical Co Ltd
- Market cap
- KRW 128B
- P/E
- 13.7x
- P/B
- 0.62x
- ROE
- -8.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 271980.KO undervalued?
Graham number271980.KO trades 38.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jeil Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jeil Pharmaceutical Co Ltd yet.
Jeil Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.
Full company profileJeil Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jeil Pharmaceutical Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 372B | 627B | 671B | 691B | 701B | 722B | 726B | 705B | 567B | 554B |
| Gross Profit | 77.0B | 139B | 152B | 157B | 156B | 157B | 184B | 177B | 213B | 226B |
| Operating Income | 4.97B | 7.39B | 375M | 12.9B | -10.4B | -13.3B | 8.89B | -18.5B | 21.0B | -13.1B |
| EBITDA | 8.23B | 13.1B | 7.88B | 22.6B | -2.73B | -1.35B | 17.7B | -10.6B | 51.7B | 2.42B |
| Net Income | 1.07B | 1.89B | -10.6B | 6.92B | -12.5B | -13.1B | 5.00B | -30.0B | 23.4B | -16.7B |
| EPS | 73 | 129 | -724 | 473 | -854 | -898 | 343 | -2,057 | 1,590 | -1,133 |
| Balance Sheet | ||||||||||
| Total Assets | 414B | 403B | 402B | 410B | 426B | 457B | 487B | 526B | 511B | 526B |
| Total Liabilities | 236B | 218B | 232B | 237B | 259B | 301B | 330B | 306B | 260B | 273B |
| Shareholders' Equity | 178B | 185B | 170B | 172B | 168B | 158B | 159B | 188B | 211B | 206B |
| Cash & Short-term Investments | 16.2B | 2.50B | 13.5B | 3.89B | 26.0B | 31.4B | 33.0B | 53.5B | 48.9B | 58.5B |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.21B | 21.5B | 29.0B | -19.0B | 19.1B | -15.1B | -4.98B | 3.21B | -5.69B | -33.7B |
| Capital Expenditure | 4.00B | 10.3B | 1.09B | 2.41B | 5.34B | 17.0B | 9.58B | 6.61B | 9.08B | 17.4B |
| Free Cash Flow | -8.21B | 11.2B | 27.6B | -21.9B | 13.7B | -32.1B | -14.6B | -3.40B | -14.8B | -51.0B |
| Ratios | ||||||||||
| ROE | 0.6% | 1.0% | -6.2% | 4.0% | -7.4% | -8.3% | 3.2% | -15.9% | 11.1% | -8.1% |
| ROA | 0.3% | 0.5% | -2.6% | 1.7% | -2.9% | -2.9% | 1.0% | -5.7% | 4.6% | -3.2% |
| Net Profit Margin | 0.3% | 0.3% | -1.6% | 1.0% | -1.8% | -1.8% | 0.7% | -4.3% | 4.1% | -3.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jeil Pharmaceutical Co Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | KRW 728M | 50 | - |
| 2023 | KRW 728M | 50 | 14.6% |
| 2022 | KRW 948M | 65 | - |
| 2021 | KRW 1.02B | 70 | - |
| 2020 | KRW 1.02B | 70 | 14.8% |
| 2019 | KRW 875M | 60 | - |
| 2018 | KRW 735M | 50 | 38.9% |
| 2017 | KRW 735M | 50 | 68.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Apr 11, 2018.
Who owns Jeil Pharmaceutical Co Ltd
- Insiders 62.46%
- Institutions 0.34%
- Public & others 37.20%
- Shares outstanding 14.7M
- Free float 5.52M
Jeil Pharmaceutical Co Ltd company profile
- Company name
- Jeil Pharmaceutical Co Ltd
- Ticker
- 271980.KO
- ISIN
- KR7271980005
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,024
- Fiscal year end
- December
- Address
- 343, Sapyeong-daero, Seoul, South Korea, 06543
- Phone
- 82 2 549 7451
- Website
- jeilpharm.co.kr
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.